| Literature DB >> 33578709 |
Tsvetelina Velikova1, Boris Krastev2, Stefan Lozenov3, Radostina Gencheva2, Monika Peshevska-Sekulovska4, Georgi Nikolaev5, Milena Peruhova4.
Abstract
The interplay between drugs and microbiota is critical for successful treatment. An accumulating amount of evidence has identified the significant impact of intestinal microbiota composition on cancer treatment response, particularly immunotherapy. The possible molecular pathways of the interaction between immune checkpoint inhibitors (ICIs) and the microbiome can be used to reverse immunotherapy tolerance in cancer by using various kinds of interventions on the intestinal bacteria. This paper aimed to review the data available on how the antibiotic-related changes in human microbiota during colorectal cancer (CRC) treatment can affect and determine ICI treatment outcomes. We also covered the data that support the potential intimate mechanisms of both local and systemic immune responses induced by changes in the intestinal microbiota. However, further better-powered studies are needed to thoroughly assess the clinical significance of antibiotic-induced alteration of the gut microbiota and its impact on CRC treatment by direct observations of patients receiving antibiotic treatment.Entities:
Keywords: antibiotics; cancer; checkpoint inhibitors; colorectal carcinoma; gut microbiota; immunotherapy; microbiome
Mesh：
Substances：
Year: 2021 PMID： 33578709 PMCID： PMC7916407 DOI： 10.3390/ijms22041754
Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923